Last reviewed · How we verify

Suprane (desflurane), Baxter — Competitive Intelligence Brief

Suprane (desflurane), Baxter (Suprane (desflurane), Baxter) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Volatile anesthetic. Area: Anesthesiology.

marketed Volatile anesthetic GABA-A receptor, NMDA receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Suprane (desflurane), Baxter (Suprane (desflurane), Baxter) — Medical University of Gdansk. Desflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Suprane (desflurane), Baxter TARGET Suprane (desflurane), Baxter Medical University of Gdansk marketed Volatile anesthetic GABA-A receptor, NMDA receptor
Volatile anesthetic Volatile anesthetic London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's marketed Volatile anesthetic GABA-A receptor, NMDA receptor
sevoflurane in step up concentration sevoflurane in step up concentration University Hospital, Ghent marketed Volatile general anesthetic GABA-A receptor, NMDA receptor
Sevoflurane Inhalation Liquid Sevoflurane Inhalation Liquid Damanhour Teaching Hospital marketed Volatile general anesthetic GABA-A receptor, NMDA receptor
original sevoflurane original sevoflurane Asan Medical Center marketed Volatile anesthetic GABA-A receptor, NMDA receptor
Sevoflurane, Isoflurane, Desflurane Sevoflurane, Isoflurane, Desflurane University Hospital, Basel, Switzerland marketed Volatile anesthetic GABA-A receptor, NMDA receptor
Sevoflurane/Ultane Sevoflurane/Ultane Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Volatile general anesthetic GABA-A receptor, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Volatile anesthetic class)

  1. Medical University of Gdansk · 2 drugs in this class
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  3. Federal University of São Paulo · 1 drug in this class
  4. King's College Hospital NHS Trust · 1 drug in this class
  5. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 1 drug in this class
  6. The Cleveland Clinic · 1 drug in this class
  7. University Hospital, Basel, Switzerland · 1 drug in this class
  8. Asan Medical Center · 1 drug in this class
  9. University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Suprane (desflurane), Baxter — Competitive Intelligence Brief. https://druglandscape.com/ci/suprane-desflurane-baxter. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing